

L2 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

=> d L1

L1 HAS NO ANSWERS

L1 SCR 963 AND 1006 AND 2076

=> s L2

SAMPLE SEARCH INITIATED 10:23:32 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 10 TO ITERATE

100.0% PROCESSED 10 ITERATIONS

1 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

BATCH **COMPLETE**

PROJECTED ITERATIONS: 11 TO 389

PROJECTED ANSWERS: 1 TO 80

L4 1 SEA SSS SAM L2

=> s L2 full

FULL SEARCH INITIATED 10:23:47 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 235 TO ITERATE

100.0% PROCESSED 235 ITERATIONS

23 ANSWERS

SEARCH TIME: 00.00.01

L5 23 SEA SSS FUL L2

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

172.55

172.76

FILE 'CAPLUS' ENTERED AT 10:23:52 ON 06 JUL 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 6 Jul 2007 VOL 147 ISS 3

FILE LAST UPDATED: 5 Jul 2007 (20070705/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s L5

L6

2 L5

=> d L6 1-2 bib abs hitstr

L6 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2005:324121 CAPLUS

DN 142:392179

TI Preparation of acyloxydiphenylbutenylcinnamates as estrogen receptor
modulator prodrugs.IN Eaddy, John Fred, III; Heyer, Dennis; Katamreddy, Subba Reddy; Martin,
Michael Tolar; McClure, Michael Scott; Randhawa, Amarjit Sab; Samano,
Vicente; Ray, John Albert

PA Smithkline Beecham Corporation, USA

SO PCT Int. Appl., 78 pp.


CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005033056	A2	20050414	WO 2004-US32918	20041004
	WO 2005033056	A3	20050623		
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,				
	CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,				
	GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,				
	LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,				
	NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,				
	TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW,				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,				
	AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,				
	EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,				
	SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,				
	SN, TD, TG				
	EP 1692127	A2	20060823	EP 2004-809876	20041004
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				
	IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, HR				
	US 2007111971	A1	20070517	US 2006-575038	20060406
PRAI	US 2003-509678P	P	20031008		
	US 2003-514692P	P	20031027		
	WO 2004-US32918	W	20041004		
OS	CASREACT 142:392179; MARPAT 142:392179				
GI					



AB Title compds. (I; R1 = ACO, PO3H2; A = alkyl, aryl, heteroaryl, cycloalkyl, aminoalkyl, alkoxy, alkoxyalkyl, haloalkyl, heterocyclylalkyl), were prepared Thus, I (R1 = H) (preparation given) and Et3N

in THF at 5° were treated with propionyl chloride in THF followed by stirring for 1 h to give 64% I (R1 = EtCO). The latter orally in rats showed 86.6% bioavailability, vs. 5.7% for I (R1 = H).

IT 850005-11-7P 850005-12-8P 850005-13-9P
850005-14-0P 850005-15-1P 850005-17-3P
850005-18-4P 850005-20-8P 850005-21-9P
850005-23-1P 850005-24-2P 850005-25-3P
850005-26-4P 850005-27-5P 850005-28-6P
850005-30-0P 850005-31-1P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(claimed compound; preparation of acyloxydiphenylbutenylcinnamates as estrogen

receptor modulator prodrugs)

RN 850005-11-7 CAPLUS

CN 2-Propenoic acid, 3-[4-[(1Z)-1-[4-(1-oxopropoxy)phenyl]-2-phenyl-1-butenyl]phenyl]-, (2E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 850005-12-8 CAPLUS

CN 2-Propenoic acid, 3-[4-[(1Z)-1-[4-(benzoyloxy)phenyl]-2-phenyl-1-butenyl]phenyl]-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 850005-13-9 CAPLUS

CN 2-Propenoic acid, 3-[4-[(1Z)-1-[4-(acetyloxy)phenyl]-2-phenyl-1-

butenyl]phenyl]-, (2E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 850005-14-0 CAPLUS

CN Butanoic acid, 4-[(1Z)-1-[4-[(1E)-2-carboxyethenyl]phenyl]-2-phenyl-1-butenyl]phenyl ester (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 850005-15-1 CAPLUS

CN 2-Furancarboxylic acid, 4-[(1Z)-1-[4-[(1E)-2-carboxyethenyl]phenyl]-2-phenyl-1-butenyl]phenyl ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 850005-17-3 CAPLUS


CN 2-Propenoic acid, 3-[4-[(1Z)-1-[4-[[[(dimethylamino)acetyl]oxy]phenyl]-2-phenyl-1-butenyl]phenyl]-, (2E)-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 850005-16-2

CMF C29 H29 N O4


Double bond geometry as shown..



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 850005-18-4 CAPLUS

CN 5-Isoxazolecarboxylic acid, 4-[(1Z)-1-[4-[(1E)-2-carboxyethenyl]phenyl]-2-phenyl-1-butenyl]phenyl ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 850005-20-8 CAPLUS


CN 2-Thiophenecarboxylic acid, 4-[(1Z)-1-[4-[(1E)-2-carboxyethenyl]phenyl]-2-phenyl-1-butenyl]phenyl ester, compd. with trifluoroacetic acid (10:1) (9CI) (CA INDEX NAME)

CM 1

CRN 850005-19-5

CMF C30 H24 O4 S


Double bond geometry as shown.



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 850005-21-9 CAPLUS

CN 2-Propenoic acid, 3-[4-[(1Z)-1-[4-(3-methoxy-1-oxopropoxy)phenyl]-2-phenyl-1-butenyl]phenyl]-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 850005-23-1 CAPLUS

CN Butanoic acid, 4,4,4-trifluoro-, 4-[(1Z)-1-[4-[(1E)-2-carboxyethenyl]phenyl]-2-phenyl-1-butenyl]phenyl ester, compd. with


trifluoroacetic acid (20:7) (9CI) (CA INDEX NAME)

CM 1

CRN 850005-22-0

CMF C29 H25 F3 O4


Double bond geometry as shown.



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 850005-24-2 CAPLUS

CN 2-Propenoic acid, 3-[4-[(1Z)-1-[4-(2,2-dimethyl-1-oxopropoxy)phenyl]-2-phenyl-1-butenyl]phenyl]-, (2E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 850005-25-3 CAPLUS

CN Cyclohexanecarboxylic acid, 4-[(1Z)-1-[4-[(1E)-2-carboxyethenyl]phenyl]-2-phenyl-1-butenyl]phenyl ester (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 850005-26-4 CAPLUS

CN 4-Morpholineacetic acid, 4-[(1Z)-1-[4-[(1E)-2-carboxyethenyl]phenyl]-2-phenyl-1-butenyl]phenyl ester (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 850005-27-5 CAPLUS

CN 1-Piperidineacetic acid, 4-[(1Z)-1-[4-[(1E)-2-carboxyethenyl]phenyl]-2-phenyl-1-butenyl]phenyl ester (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 850005-28-6 CAPLUS

CN 1-Piperazineacetic acid, 4-methyl-, 4-[(1Z)-1-[4-[(1E)-2-carboxyethenyl]phenyl]-2-phenyl-1-butenyl]phenyl ester (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 850005-30-0 CAPLUS

CN 2-Propenoic acid, 3-[4-[(1Z)-1-[4-[(ethoxycarbonyl)oxy]phenyl]-2-phenyl-1-butenyl]phenyl]-, (2E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 850005-31-1 CAPLUS

CN 2-Propenoic acid, 3-[4-[(1Z)-1-[4-[(methoxycarbonyl)oxy]phenyl]-2-phenyl-1-butenyl]phenyl]-, (2E)-(9CI) (CA INDEX NAME)

Double bond geometry as shown.



IT 850005-16-2P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of acyloxydiphenylbutenylcinnamates as estrogen receptor modulator prodrugs)

RN 850005-16-2 CAPLUS


CN 2-Propenoic acid, 3-[4-[(1Z)-1-[4-[[[(dimethylamino)acetyl]oxy]phenyl]-2-phenyl-1-butenyl]phenyl]-, (2E)-(9CI) (CA INDEX NAME)

Double bond geometry as shown.




IT 850005-37-7P 850005-45-7P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation of acyloxydiphenylbutenylcinnamates as estrogen receptor
 modulator prodrugs)
 RN 850005-37-7 CAPLUS
 CN 2-Propenoic acid, 3-[4-[(1Z)-1-(4-methoxyphenyl)-2-phenyl-1-
 butenyl]phenyl]-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 850005-45-7 CAPLUS
 CN 2-Propenoic acid, 3-[4-[(1Z)-1-[4-[(chloroacetyl)oxy]phenyl]-2-phenyl-1-
 butenyl]phenyl]-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



L6 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 2001:430866 CAPLUS
 DN 135:235901
 TI Differential SERM activation of the estrogen receptors (ER α and ER β) at AP-1 sites
 AU Weatherman, Ross V.; Clegg, Nicola J.; Scanlan, Thomas S.
 CS Departments of Pharmaceutical Chemistry and Cellular and Molecular Pharmacology, University of California, San Francisco, CA, 94143-0446, USA
 SO Chemistry & Biology (2001), 8(5), 427-436
 CODEN: CBOLE2; ISSN: 1074-5521
 PB Elsevier Science Ltd.
 DT Journal
 LA English
 AB Background: The selective estrogen receptor modulators (SERMs) raloxifene and tamoxifen are triphenylethylene derivs. that affect transcriptional regulation by the estrogen receptors (ER α and ER β) but show different effects in different tissues. A third triphenylethylene derivative, GW-5638, displays tissue selectivity in rats identical to that of raloxifene, suggesting that GW-5638 and raloxifene share a mechanism of action that is different from that of tamoxifen. Results: Both GW-5638 and its hydroxylated analog GW-7604 were tested for their ability to bind to ER α and ER β and their ability to affect transcription of ER α and ER β at a consensus estrogen response element and an ER/AP-1 response element. The drugs were found to have the same affinity for ER α and ER β , although they were also found to activate transcription from an AP-1 promoter element more potently with ER β than with ER α . Derivs. of GW-5638 with alterations at the carboxylic acid still showed increased ER β potency compared to ER α , but the magnitude of the activation with ER α was much higher than with ER β . Conclusions: Despite similar binding affinities to isolated ER α and ER β , GW-5638 and GW-7604 show markedly lower EC50 values with ER β at an AP-1-driven promoter as compared to ER α . This suggests that the two compds. produce a more active ER/AP-1 conformation of the ER/AP-1 transcription factor complex when bound to ER β than when bound to ER α .
 IT 361203-04-5P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (differential SERM activation of estrogen receptors at AP-1 sites)
 RN 361203-04-5 CAPLUS
 CN 2-Propenoic acid, 3-[4-[1-[4-(1,1-dimethylethoxy)phenyl]-2-phenyl-1-butenyl]phenyl]-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as described by E or Z.



RE.CNT 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=>

---Logging off of STN---

=>

Executing the logoff script...

=> LOG Y

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	11.01	183.77
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	-1.56	-1.56

STN INTERNATIONAL LOGOFF AT 10:24:25 ON 06 JUL 2007